Introduction
Recent clinical advances in breast cancer immunotherapy
Immune checkpoint inhibitors
Monoclonal antibodies
Sl. No | Type of Therapy | Breast Cancer Subtype | Clinical Trial Identifier | Phase | References |
---|---|---|---|---|---|
1 | ZW25 (zanidatamab) plus palbociclib plus fulvestrant | HER2+/HR+ | NCT04224272 | II | 50 |
2 | Tucatinib plus Trastuzumab | HER2+ | NCT02614794 | II | 56 |
3 | Ladiratuzumab vedotin plus trastuzumab | TNBC | NCT01969643 | I | 61 |
4 | Datopotamab deruxtecan plus paclitaxel, nab-paclitaxel, carboplatin, capecitabine, eribulin mesylate | TNBC | NCT05374512 | III | 64 |
5 | Datopotamab deruxtecan plus ICC eribulin, capecitabine, vinorelbine, or gemcitabine | Inoperable or metastatic HR+, HER2- breast cancer | NCT05104866 | III | 65 |
6 | Glembatumumab vedotin (CDX-011) plus capecitabine | Metastatic TNBC | NCT01997333 | II | 67 |
7 | Sacituzumab govitecan (IMMU-132) plus Pembrolizumab | TNBC | NCT04230109 | II | 68 |
8 | Sacituzumab govitecan (IMMU-132) plus Pembrolizumab | TNBC | NCT04468061 | II | 68 |
9 | Multiple drug treatment (Capecitabine, atezolizumab, ipatasertib, sgn-liv1a, bevacizumab, chemotherapy (gemcitabine, carboplatin or eribulin), selicrelumab, tocilizumab, nab-paclitaxel, sacituzumab govitecan, abemaciclib, fulvestrant, ribociclib, inavolisib, trastuzumab deruxtecan) | Metastatic | NCT03424005 | Ib/II | 68 |
10 | MUC-1 peptide vaccine | TNBC | NCT00986609 | I | 81 |
11 | Dendritic cells | Ductal | NCT03450044 | I/II | 95 |
12 | Autologous dendritic cell vaccine | HER2- | NCT01431196 | II | 96 |
13 | AdHER2/neu dendritic cell vaccine | HER2+ | NCT01730118 | I | 97 |
14 | HER-2/neu pulsed DC1 vaccine | HER2+ | NCT02061332 | I/II | 98 |
15 | HER-2/neu pulsed DC1 vaccine | HER2+ | NCT00107211 | I | 99 |
16 | Nab-paclitaxel | Metastatic | NCT00821964 | II | 101 |
17 | Pembrolizumab plus Flt3L | Metastatic | NCT03789097 | I/II | 102 |
18 | huMNC2-CAR44 CAR T cells | Metastatic | NCT04020575 | I | 103 |
19 | cMet RNA CAR T cells | TNBC | NCT01837602 | I | 103 |
20 | Anti-meso-CAR vector transduced T cells | TNBC | NCT02580747 | I | 104 |
21 | CAR macrophages | HER2+ | NCT04660929 | I | 106 |
22 | Entinostat plus atezolizumab | TNBC | NCT02708680 | I/II | 254 |
23 | Entinostat plus ipilimumab and nivolumab | HER2-, TNBC | NCT02453620 | II | 255 |
24 | Imprime PGG plus pembrolizumab | TNBC | NCT02981303 | II | 290 |
25 | PLX3397 plus eribulin | Metastatic | NCT01596751 | I/II | 291 |